Elapegademase

From Wikipedia, the free encyclopedia
Elapegademase
Clinical data
Trade namesRevcovi
Other nameselapegademase-lvlr
AHFS/Drugs.comMonograph
License data
Routes of
administration		Intramuscular
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG

Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults.

It is a recombinant enzyme[1] that is administered weekly by intramuscular injection.[2]

Elapegademase may interact with PEGylated drugs.[2]

Elapegademase-lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018.[3][4][5] Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program.[6]

References[]

  1. ^ "Elapegademase: Drug Information". www.uptodate.com. Retrieved 28 March 2019.
  2. ^ a b "LexiComp: Elapegademase-lvlr". LexiComp. Retrieved 28 March 2019.
  3. ^ "Drug Approval Package: Revcovi". U.S. Food and Drug Administration (FDA). 7 November 2018. Retrieved 26 December 2019.
  4. ^ "Elapegademase-lvlr Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 26 December 2019.
  5. ^ "Drug Trial Snapshot: Revcovi". U.S. Food and Drug Administration (FDA). 5 October 2018. Retrieved 26 December 2019.
  6. ^ "Elapegademase - Leadiant Biosciences". AdisInsight. Springer Nature Switzerland AG. Retrieved 28 March 2019.

External links[]

  • "Elapegademase". Drug Information Portal. U.S. National Library of Medicine.


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""